Literature DB >> 20393242

The value of an acute octreotide suppression test in predicting response to long-term somatostatin analogue therapy in patients with acromegaly.

T R Bandgar1, V Sarathi, V Shivane, N Bansode, P S Menon, N S Shah.   

Abstract

CONTEXT: The usefulness of the acute octreotide test in the selection of patients with acromegaly for chronic somatostatin depot analogues treatment is controversial. AIMS: To determine the efficacy of acute octreotide suppression test (OST) in predicting response to long-term somatostatin analogue (Octreotide-long-acting repeatable, OCT-LAR) therapy in patients with acromegaly. SETTINGS AND
DESIGN: Prospective study (2006-2007) conducted at a tertiary healthcare centre in western India.
MATERIALS AND METHODS: Sixteen drug-naive patients with active acromegaly (postoperative+/-post radiotherapy) underwent 50 microg subcutaneous OST. Ten patients were treated with OCT-LAR for one year. Remission was defined as a nadir growth hormone (GH) < 1 ng/ml during 75 g oral glucose tolerance test (OGTT) (0, 10, 30, 60, 120, 180 min) and normal age, sex-matched insulin-like growth factor 1 (IGF1) levels. STATISTICAL ANALYSIS: SPSS Software Version 11 was used for data analysis.
RESULTS: Using GH cutoff.
CONCLUSIONS: Nadir GH < 1 ng/ml following an OST is a useful predictive marker of achieving disease remission with long-term OCT-LAR therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20393242     DOI: 10.4103/0022-3859.62421

Source DB:  PubMed          Journal:  J Postgrad Med        ISSN: 0022-3859            Impact factor:   1.476


  3 in total

1.  Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases.

Authors:  Tanya Burton; Elisabeth Le Nestour; Tim Bancroft; Maureen Neary
Journal:  Pituitary       Date:  2013-09       Impact factor: 4.107

Review 2.  Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly.

Authors:  Annamaria Colao; Renata S Auriemma; Rosario Pivonello; Leandro Kasuki; Mônica R Gadelha
Journal:  Pituitary       Date:  2016-06       Impact factor: 4.107

3.  Expression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin Analogues.

Authors:  Wenjuan Liu; Lina Xie; Min He; Ming Shen; Jingjing Zhu; Yeping Yang; Meng Wang; Ji Hu; Hongying Ye; Yiming Li; Yao Zhao; Zhaoyun Zhang
Journal:  Int J Endocrinol       Date:  2017-03-15       Impact factor: 3.257

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.